ClinicalTrials.gg
CompletedNCT04471610Updated Jul 17, 2020

Point Of Care With Serial NT-proBNP Measurement in Patients With Acute Decompensation of Heart Failure

An interventional study of Serial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day in Acute Decompensated Heart Failure, sponsored by Prof. Dr. Jörg Leuppi. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-17.

Sponsored by Prof. Dr. Jörg Leuppi · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Jan 2018, registered Jul 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 149 studies in Heart Failure with a site in Switzerland — 21 open to participants now, 32 under way, 1 of them phase 3. Heart Failure · Switzerland.

Enrollment
77th of 100
52 · median 314
Started
2018
with 8 others
No phase
50 of 149
8 open now
Registered
119th of 149
by date

Among the 149 studies in Heart Failure with a site in Switzerland, this one is the 77th largest by enrollment of the 100 interventional ones that give a count, is one of 9 that started in 2018, is one of 50 with no phase, and was the 119th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

21 of the 149 studies in Heart Failure with a site in Switzerland are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Heart Failure with a site in Switzerland, or all of them as a file.
02

Study summary

The goal of this study is to explore whether the availability of serial NT-proBNP measurements together with safety parameters such as electrolytes and creatinine may influence treatment decision in patients with acute decompensated heart failure (ADHF) leading to more rapid and faster dose increase of prognostic therapies and earlier hospital discharge.

Read the detailed description

The proposed study is a prospective, unblinded, single center, 2-arm randomized controlled pilot trial. In the intervention arm serial measurement of NT-proBNP will be made available to the treating physician. A control group continuing to undergo care according to the 2016 ESC Guidelines will serve as comparator. Changes in NT-proBNP levels, safety laboratory parameters such as sodium, potassium, creatinine, Heart failure (HF) medication, vital signs, body weight and BMI, Quality of Life (QoL), length of hospital stay, New York Heart Association (NYHA) functional class, adverse events, transfer to the Intensive Care Unit and mortality will be recorded in patients with ADHF.

The Kantonsspital Baselland (KSBL) Liestal will be the only study center. All members of the study group will the thoroughly instructed regarding study procedures. Inclusion visits will be conducted only by a member of the study group. All Patients with ADHF on the medical ward of the KSBL Liestal will be provided an information sheet regarding goals and procedures of the study and the informed consent. Inclusion criteria will be checked after admission. Patients not matching the inclusion criteria at the screening visit cannot participate in this study. Patients will be provided sufficient time for their decision. The investigators communicate clearly that participation in the study is absolutely voluntary and refusal of participation has no influence on treatment during hospitalization.

In order to minimize bias that may be introduced by even minor differences in executing and interpreting technical exams, all study related measurements and procedures will be performed in a centralized manner at the KSBL Liestal.

Patients will be included only after approval of informed consent. Randomization is performed using 50 closed envelopes containing a paper shit with either the letter A or B. In total there are 25 A's and 25 B's. The letter A stands for the control group and the letter B for the intervention group. These envelopes are mixed initially, numbered for order purposes and the order maintained throughout the study. The name of the patient will be written down on the envelope. Then it will be open and the patient will be allocated to the study group depending on the letter in the envelope. All patients will undergo an inclusion and discharge visit. General demographic data, including age, gender, nationality, smoking status, alcohol consumption, current profession, exercise behavior, allergies, medication, HF history and comorbidities will be recorded. Assessment of vital signs and body weight will be performed together with an electrocardiogram, several laboratory tests (NT-proBNP, potassium, sodium and creatinine). In addition, questionnaires concerning QoL (SF-12, KCCQ, MLWHFQ) will be filled in by the participants. Women who can get pregnant (not yet in menopause and last menstrual period less than 12 months, not surgically sterilized, ovaries and/or uterus not removed) will have to undergo a pregnancy test prior to inclusion into the study.

Patients allocated to the intervention group (POC-available group) will undergo serial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day. The investigators have chosen this time-lag because an earlier time point would not show the change of the security parameter creatinine due to longer half-life-time. For this test, blood is collected from the patients. These samplings will be done in the morning together with the regularly blood collection through the attending nurse according to the established procedure of the KSBL Liestal in the morning. 10ml blood will be collected for this study during each blood sample with a standard Lithium-blood-collection tube. Members of the study team will collect the blood samples and analyses them on the study devices. The result of the test will be provided directly to the responsible physician of the medical department at the KSBL Liestal. Treatment changes are at the discretion of the responsible physician. The physician will be alerted by a phone call of a study member if the NT-proBNP hasn't decreased by 10% or more between two measurements. But no specific recommendations with regards to therapy will be provided by the investigator or his team. However, diagnostic and therapeutic decisions will be based on the current 2016 ESC guidelines on the diagnosis and therapy of HF as established at the KSBL Liestal.

Patients allocated to the control group will undergo the measurements at inclusion and discharge visit. The control group conduces to compare the NT-proBNP and HF medication changes under therapy monitoring with serial NT-proBNP measurements to the NT-proBNP and HF medication changes with sign and symptom guided HF therapy. As in the intervention group, diagnostic and therapeutic decisions in the control group will be based on the current 2016 ESC guidelines on the diagnosis and therapy of HF as established at the KSBL Liestal. At discharge, the same measurements as at the inclusion visit will be repeated in all patients to monitor the effects associated with the participation in this trial.

Total study duration will cover a period of approximately 3 years. Patients will be screened until a total of 25 patients are included per study group.

Overall, 50 patients are planned to be recruited. Recruitment is estimated to start in September 2017 and end at the latest in March 2020 after discharge of the last hospitalized patient included in the study. Data collection of the study is expected to be completed by May 2020 and data analysis by December 2020.

The expected duration of the study for each patient will be defined by the time period from inclusion to discharge and is expected to be in the range of 8-12 days (=average time for HF hospitalization of our institution).

As an university institution, the KSBL Liestal mandates its physician and nursing staff to provide evidence-based medical care and to follow recognized and established national and/or international guidelines whenever possible. Nevertheless, deviation from guidelines may be necessary in specific cases. The decision whether and when to deviate from guidelines is at the discretion of the responsible physician and nursing staff and is taken to the best individual knowledge. Patients with ADHF admitted to the Intensive Care Unit are not included in this study. Patients not requiring intensive care treatment will be hospitalized on a regular medical ward and treated with diuretics to improve symptoms of congestion. In case a patient is transferred to the Intensive Care Unit after study inclusion, further data from date of transfer onwards will not be collected, to avoid discomfort to patients and medical personal while the patient is in a critical situation. The study itself is also composed for treatments on a regular medical ward. The transfer to the Intensive Care Unit will serve as the endpoint.

03

Conditions studied

  • Acute Decompensated Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • functional class II or III
  • Symptoms of heart failure:

E.g.: Dyspnea Paroxysmal nocturnal dyspnea Reduced exercise capacity Fatigue Extended recovery after exercising Peripheral edema (lower leg, ankle) NT-proBNP >300 (pg/ml)

  • Age > 18 Years

Exclusion criteria

Exclusion Criteria:

  • functional class I or IV
  • NT-proBNP \< 1200 pg/ml and \< 60 ml/min (Clearance (ml/min) = 1.23(women 1.03) x body weight (Kg) x (140-Age)/ creatinine (umol/L)) Creatinine clearence: ___________ \<60ml/min
  • Heart failure due to chemotherapeutic drugs
  • Uncontrolled brady- or tachyarrythmia
  • Unstable angina pectoris
  • Severe uncorrected valvular disease
  • Planned cardiac intervention in the next 6 months
  • concomitant disease states:

On-going cancer treatment

  • Active infection
  • medical therapy
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow the study procedures (Due to language problems, psychological disorders, dementia, etc.)
  • Participation in another intervention study
  • Enrolment of investigators or their family members
  • Pregnancy, lactation, breast feeding
  • Positive pregnancy test for females in childbearing age
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • No intervention
    Control group

    Group A: Patients allocated to the control group will undergo the measurements at inclusion and discharge visit. The control group conduces to compare the NT-proBNP and HF medication changes under therapy monitoring with serial NT-proBNP measurements to the NT-proBNP and HF medication changes with sign and symptom guided HF therapy. The diagnostic and therapeutic decisions in the control Group and in the Intervention group will be based on the current 2016 ESC guidelines on the diagnosis and therapy of HF as established at the KSBL Liestal. At discharge, the same measurements as at the inclusion visit will be repeated in all patients to monitor the effects associated with the participation in this trial.

  • Experimental
    POC-available group

    Group B:Patients allocated to the intervention group (POC-available group) will undergo serial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day. The blood collection (10 ml of Lithium Heparin blood) for these tests will be done in the morning together with the regularly blood collection. The study team does the the analysis on the study devices. The result of the test will be provided directly to the responsible physician. Treatment changes are at the discretion of the responsible physician. The physician will be alerted by a phone call of a study member if the NT-proBNP hasn't decreased by 10% or more between two measurements. But no specific recommendations with regards to therapy will be provided by the investigator or his team. However, diagnostic and therapeutic decisions will be based on the current 2016 ESC guidelines on the diagnosis and therapy of HF as established at the KSBL Liestal.

    Other: Serial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day

Interventions

  • OtherSerial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day

    Serial measurements of NT-proBNP, sodium, potassium, and creatinine in the NT-proBNP-group vs. no serial measurements in control group. In the intervention group the body weight, vital parameters, therapy changes and adverse events are documented the above mention serial measurement every second business day.

06

What researchers measure

Primary outcomes

  1. Changes in NT-proBNP

    Meassurement of NT-proBNP

    Time frame: Up to 4 weeks, on average 10 days

  2. Dosage and variations in medication to treat heart failure

    Changes in medical heart failure therapies such as Diuretics, Nitrates, Angiotensin-converting-enzyme (ACE) Inhibitors or angiotensin-receptor blockers (ARBs), Beta blocker

    Time frame: Up to 4 weeks, on average 10 days

Secondary outcomes

  1. HR (in beats/min)

    Vital signs

    Time frame: Up to 4 weeks, on average 10 days

  2. BP (in mmHg)

    Vital sign

    Time frame: Through study completion, on average 10 days

  3. BMI and Body weight

    Body mass index and weight in kg

    Time frame: Up to 4 weeks, on average 10 days

  4. KCCQ (Kansas City Cardiomyopathy ) Questionnaire

    The KCCQ is a self-administered, 23-item questionnaire measuring HRQoL in patients with CHF regardless of its origin. Each item has a 5-, 6-, or 7-point Likert scale. The questionnaire assesses six domains of HRQoL: Physical Limitation, Symptoms, Symptom Stability, Social Limitation, Self-Efficacy, and Quality of Life. Domain scores were transformed to 0-100 (highest level of functioning) scales.

    Time frame: Up to 4 weeks, on average 10 days

  5. SF12 (Short Form 12 Health Survey ) Questionnaire

    A mental component score (MCS-12) and a physical component score (PCS-12). The scores may be reported as Z-scores (difference compared to the population average, measured in standard deviations). The United States population average PCS-12 and MCS-12 are both 50 points. The United States population standard deviation is 10 points. So each 10 increment of 10 points above or below 50, corresponds to one standard deviation away from the average.

    Time frame: Up to 4 weeks, on average 10 days

  6. Minnesota LIVING WITH HEART FAILURE® Questionnaire

    The questionnaire is comprised of 21 important physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. After receiving brief standardized instructions, the patient marks a 0 (zero) to 5 scale to indicate how much each itemized adverse of heart failure has prevented the patient from living as he or she wanted to live during the past 4 weeks. The questionnaire is simply scored by summation of all 21 responses. The instrument can be used as a key outcome measure in studies and evaluations of outpatients with symptomatic (NYHA class II to IV) heart failure with a reduced or preserved ejection fraction. This patient-reported outcome can be used to determine whether a treatment for heart failure is effective for improving patients' quality of life by reducing the adverse impact of heart failure.

    Time frame: Up to 4 weeks, on average 10 days

  7. Potassium

    Meassurement of potassium as safety parameter

    Time frame: Up to 4 weeks, on average 10 days

  8. Sodium

    Meassurement of sodium as safety parameter

    Time frame: Up to 4 weeks, on average 10 days

  9. Creatinine

    Meassurement of creatinine as safety parameter

    Time frame: Up to 4 weeks, on average 10 days

  10. Length of hospital stay

    Days spent in the hospital

    Time frame: Up to 4 weeks, on average 10 days

  11. NYHA functional class

    NYHA class I-IV

    Time frame: Up to 4 weeks, on average 10 days

  12. Transfer to the Intensive Care Unit (ICU)

    Stay at ICU

    Time frame: Number pf patients

07

Study locations

1 site
  • Cantonal Hospital Baselland Liestal
    Liestal, BL 4410, Switzerland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in May 2020, 27 months.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's 27 months is close to that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2020
First posted
Jul 15, 2020
StartActual
Jan 23, 2018
Primary completionActual
May 20, 2020
CompletionActual
May 20, 2020
Last update
Jul 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04471610
Lead sponsor
Prof. Dr. Jörg Leuppi
Responsible party
Prof. Dr. Jörg Leuppi (Professor of Internal Medicine, Cantonal Hosptal, Baselland) — Sponsor-investigator
First posted
Jul 15, 2020
Start date
Jan 23, 2018
Primary completion
May 20, 2020
Completion
May 20, 2020
Last update
Jul 17, 2020

Study contacts

Jörg D. Leuppi, Prof.
principal investigator · Head of Medical University Clinic, Cantonal hospital Baselland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion